secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001641172-25-009249
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics Q1 revenue $0.1M; net loss $7.5M; advancing platform pipeline
----------------------------------------------------------------------------

- Revenue of $0.1M, down from $0.5M YoY due to no grant revenue recognized in Q1 2025.
- Net loss of $7.5M ($0.24 loss per share) compared to net loss of $9.3M ($0.31 per share) in Q1 2024.
- Operating loss improved to $8.6M from $10.3M YoY; operating expenses decreased 18.2%.
- Cash and marketable securities totaled $21.5M as of March 31, 2025.
- On track to begin clinical evaluations for 4 tests and complete India manufacturing facility by year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000164117225009249/0001641172-25-009249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000164117225009249/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer